Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Etopophos Generic Name & Formulations
Legal Class
Rx
General Description
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Topoisomerase inhibitor.
How Supplied
Single-dose vials—1
Manufacturer
Etopophos Indications
Indications
In combination with other chemotherapeutic drugs for refractory testicular tumors.
Etopophos Dosage and Administration
Adult
Give by IV infusion over 5 to 210 minutes. 50–100mg/m2 per day on Days 1 through 5 or 100mg/m2 per day on Days 1, 3, 5 of each 21-day (or 28-day) cycle. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): consider further dose reduction.
Children
Not established.
Etopophos Contraindications
Not Applicable
Etopophos Boxed Warnings
Not Applicable
Etopophos Warnings/Precautions
Warnings/Precautions
Monitor CBCs before each cycle and as clinically indicated. Embryo-fetal toxicity. Advise use of effective contraception during therapy and for 6 months (females) or 4 months (males w. female partners) after final dose. Pregnancy, nursing mothers: not recommended.
Etopophos Pharmacokinetics
See Literature
Etopophos Interactions
Interactions
May potentiate warfarin; monitor INR. May be potentiated by cisplatin. May be antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid).
Etopophos Adverse Reactions
Adverse Reactions
Myelosuppression (esp. neutropenia, thrombocytopenia), nausea, vomiting, abdominal pain, constipation, dysphagia, fever, infections, ocular disorders, interstitial pneumonitis, pulmonary fibrosis, skin reactions, seizure, hepatotoxicity; secondary leukemias, hypersensitivity reactions (permanently discontinue if severe reaction occurs), infertility, others.
Etopophos Clinical Trials
See Literature
Etopophos Note
Not Applicable
Etopophos Patient Counseling
See Literature
Etopophos Generic Name & Formulations
Legal Class
Rx
General Description
Etoposide (as phosphate) 100mg/vial; pwd for IV infusion after reconstitution and dilution.
Pharmacological Class
Topoisomerase inhibitor.
How Supplied
Single-dose vials—1
Manufacturer
Etopophos Indications
Indications
In combination with cisplatin for small cell lung cancer.
Etopophos Dosage and Administration
Adult
Give by IV infusion over 5 to 210 minutes. 35mg/m2 per day for 4 days or 50mg/m2 per day for 5 days. Renal impairment (CrCl 15–50mL/min): reduce to 75% of dose; (<15mL/min): consider further dose reduction.
Children
Not established.
Etopophos Contraindications
Not Applicable
Etopophos Boxed Warnings
Not Applicable
Etopophos Warnings/Precautions
Warnings/Precautions
Monitor CBCs before each cycle and as clinically indicated. Embryo-fetal toxicity. Advise use of effective contraception during therapy and for 6 months (females) or 4 months (males w. female partners) after final dose. Pregnancy, nursing mothers: not recommended.
Etopophos Pharmacokinetics
See Literature
Etopophos Interactions
Interactions
May potentiate warfarin; monitor INR. May be potentiated by cisplatin. May be antagonized by antiepileptics (eg, phenytoin, phenobarbital, carbamazepine, valproic acid).
Etopophos Adverse Reactions
Adverse Reactions
Myelosuppression (esp. neutropenia, thrombocytopenia), nausea, vomiting, abdominal pain, constipation, dysphagia, fever, infections, ocular disorders, interstitial pneumonitis, pulmonary fibrosis, skin reactions, seizure, hepatotoxicity; secondary leukemias, hypersensitivity reactions (permanently discontinue if severe reaction occurs), infertility, others.
Etopophos Clinical Trials
See Literature
Etopophos Note
Not Applicable
Etopophos Patient Counseling
See Literature
